A Phase II Study of Pemetrexed/Carboplatin/Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer
The patients on this study will receive treatment in 3 stages of therapy.
The first stage is Induction Therapy. This therapy is 7 weeks long. Patients will receive
bevacizumab followed by premetrexed followed by carboplatin all by vein once a week in weeks
1 and 4. During Induction patients will also receive radiation therapy daily, Monday
through Friday, for 7 weeks (weeks 1-7). This is followed by 2 weeks of rest. During this
rest period patients will have scans done to see how their disease has responded to
The next stage of treatment is Consolidation Therapy. This stage is 10 weeks long.
Patients will receive bevacizumab followed by premetrexed followed by carboplatin all by
vein once a week in weeks 10, 13 and 16. This is followed by 3 weeks rest. During week 19
patients will have scans to see how their disease has responded to treatment.
The last stage of treatment is maintenance Therapy. Patients will receive bevacizumab alone
by vein every 3 weeks. Treatment will be given every three weeks for up to 9 treatments.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Time to progression
David Spigel, MD
Sarah Cannon Research Institute
United States: Food and Drug Administration
SCRI LUN 134
|Consultants in Blood Disorders and Cancer||Louisville, Kentucky 40207|
|Tennessee Oncology, PLLC||Clarksville, Tennessee 37043|
|Wellstar Cancer Research||Marietta, Georgia 30060|
|Oncology Hematology Care||Cincinnati, Ohio 45242|
|Watson Clinic Center for Cancer Care and Research||Lakeland, Florida 33805|
|Gainsville Hematology Oncology Associates||Gainesville, Florida 32605|
|Associates in Hematology Oncology||Chattanooga, Tennessee 37404|